Evidence map›Paper›PMID 39680203›Full record

ArticleJournal of neurology2024

Recognition memory decline is associated with the progression to prodromal Alzheimer's disease in asymptomatic at-risk individuals.

Filipa Raposo Pereira, Maximilien Chaumon, Bruno Dubois, Hovagim Bakardjian, Mahsa Bahrami, Marie-Odile Habert, Katia Andrade, Nadjia Younsi, Valentina La Corte, Nathalie George and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Filipa Raposo PereiraSorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, U 1127, CNRS, UMR 7225, AP-HP, CENIR, Centre MEG-EEG, Hôpital de La Pitié-Salpêtrière, 47 Boulevard de L'Hôpital, 75013, Paris, France. filipa.raposopereira@icm-institute.org.ORCID http://orcid.org/0000-0001-6199-7164
Maximilien ChaumonSorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, U 1127, CNRS, UMR 7225, AP-HP, CENIR, Centre MEG-EEG, Hôpital de La Pitié-Salpêtrière, 47 Boulevard de L'Hôpital, 75013, Paris, France.
Bruno DuboisSorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, U 1127, CNRS, UMR 7225, AP-HP, CENIR, Centre MEG-EEG, Hôpital de La Pitié-Salpêtrière, 47 Boulevard de L'Hôpital, 75013, Paris, France.
Hovagim BakardjianSorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, U 1127, CNRS, UMR 7225, AP-HP, CENIR, Centre MEG-EEG, Hôpital de La Pitié-Salpêtrière, 47 Boulevard de L'Hôpital, 75013, Paris, France.
Mahsa BahramiDepartment of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Pitié-Salpêtrière University Hospital, AP-HP, Paris, France.
Marie-Odile HabertSorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, 75006, Paris, France.
Katia AndradeDepartment of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Pitié-Salpêtrière University Hospital, AP-HP, Paris, France.
Nadjia YounsiDepartment of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Pitié-Salpêtrière University Hospital, AP-HP, Paris, France.
Valentina La Corte *Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Pitié-Salpêtrière University Hospital, AP-HP, Paris, France.
Nathalie George *Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, U 1127, CNRS, UMR 7225, AP-HP, CENIR, Centre MEG-EEG, Hôpital de La Pitié-Salpêtrière, 47 Boulevard de L'Hôpital, 75013, Paris, France.
INSIGHT-preAD study group

Funding

Fondation pour la Recherche sur Alzheimer ePARADInserm Transfert IDRCB: 2012-A01731-42Inserm Transfert protocol nb. C12-59Investissements d'avenir ANR-10- IAIHU-06
6 · The paper itself

Abstract

Episodic memory (EM) alterations are a hallmark of Alzheimer's disease (AD). We assessed EM longitudinally in cognitively normal elders at-risk for AD (with subjective memory complaints), as a function of amyloid-β (Aβ) burden, neurodegeneration (N), and progression to prodromal AD. We stratified 264 INSIGHT-preAD study subjects in controls (Aβ-/N-), stable/N- or N + (Aβ +), and progressors/N- or N + (Aβ +) groups (progressors were included only until AD-diagnosis). We used linear mixed-effect models with Aβ and N status, or progression to AD as factors, to analyze behavioral performance in an old/new word-recognition task based on the free and cued selective reminding test (FCSRT). The controls and stable/N- groups showed near-ceiling accuracy and RT improvement across follow-up. The stable/N + group showed accuracy reduction and no RT improvement, i.e., Aβ + /N + cumulative effect. The progressors showed a marked performance decline. EM alterations may constitute early preclinical markers of progression to prodromal AD, while individuals are cognitively normal according to neuropsychological standards.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesDisease ProgressionMemory DisordersProdromal SymptomsRecognition, PsychologyAgedAged, 80 and overAsymptomatic DiseasesFemaleHumansLongitudinal StudiesMaleMemory, EpisodicNeuropsychological TestsAmyloid beta-PeptidesAlzheimer’s disease (AD)Episodic memoryFree and cued selective reminding test (FCSRT)NeurodegenerationOld/new effectβ-amyloid

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.